Advanced in Apolipoprotein C2 Deficiency

Charlotte A. Dawson

Pembroke Place, 
Liverpool, ENG, GB 
Advanced in Apolipoprotein C2 Deficiency
Pembroke Place, 
Liverpool, ENG, GB 
OverviewLocationsClinical Research

Overview

Charlotte Dawson practices in Liverpool, United Kingdom. Ms. Dawson is rated as an Advanced expert by MediFind in the treatment of Apolipoprotein C2 Deficiency. Her top areas of expertise are Alstrom Syndrome, Familial Lipoprotein Lipase Deficiency, Apolipoprotein C2 Deficiency, and Classic Galactosemia.

Her clinical research consists of co-authoring 49 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles in the study of Apolipoprotein C2 Deficiency.

Gender
Female

Locations

Pembroke Place, Liverpool, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a Dose of 4E13vg/kg in Hemophilia A Patients With Residual FVIII Levels ≤1IU/dL Receiving Prophylactic FVIII Infusions
A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a Dose of 4E13vg/kg in Hemophilia A Patients With Residual FVIII Levels ≤1IU/dL Receiving Prophylactic FVIII Infusions
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Biological
Study Drug: Valoctocogene Roxaparvovec
Study Phase: Phase 3
A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177
A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

49 Total Publications

Fabry disease - a risk factor for renal cell cancer? - case series.
Fabry disease - a risk factor for renal cell cancer? - case series.
Journal: Molecular genetics and metabolism
Published: March 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Dawson's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile